| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab177845-100μg | 100μg | In stock | $69.90 | |
| Ab177845-1mg | 1mg | In stock | $309.90 | |
| Ab177845-5mg | 5mg | In stock | $789.90 | |
| Ab177845-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,259.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Enapotamab (anti-AXL) - Primary antibody, specific to AXL, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | AXL oncogene | EC 2.7.10.1 |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | AXL |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description | Enapotamab (anti-AXL) is an anti-AXL/UFO reference antibody. Enapotamab (anti-AXL) can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 26.4 kDa (Light Chain) & 50.8 kDa (Heavy Chain), under reducing conditions; 195.7 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1912423-61-0 |
Enapotamab (anti-AXL) (Ab177845) - Flow Cytometry
Flow Cytometry analysis of HeLa cells labelling AXL (red) with Enapotamab (anti-AXL) (Ab177845). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Enapotamab (anti-AXL) (Ab177845) - ELISA
Immobilized hu-Axl-ECD-FC(IgG1) at 2 μg/mL can bind Enapotamab (anti-AXL) (Ab177845) with the EC₅₀ of 13.86 ng/mL
Enapotamab (anti-AXL) (Ab177845) - SEC
The purity of Enapotamab (anti-AXL) (Ab177845) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0303120 | Certificate of Analysis | Mar 12, 2024 | Ab177845 |
| ZJ24F0303119 | Certificate of Analysis | Mar 12, 2024 | Ab177845 |
| ZJ24F0303118 | Certificate of Analysis | Mar 12, 2024 | Ab177845 |
| 1. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF. (1995) The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases.. Cell, 80 (4): (661-70). [PMID:7867073] [10.1021/op500134e] |
| 2. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, Mizuno K. (1996) Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases.. J Biol Chem, 271 (47): (30022-7). [PMID:8939948] [10.1021/op500134e] |
| 3. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Göhring W, Ullrich A, Timpl R, Hohenester E. (2006) Structural basis for Gas6-Axl signalling.. EMBO J, 25 (1): (80-7). [PMID:16362042] [10.1021/op500134e] |
| 4. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al.. (2012) 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.. J Med Chem, 55 (1): (403-13). [PMID:22136433] [10.1021/op500134e] |
| 5. Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H, Bearss DJ. (2011) Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.. ACS Med Chem Lett, 2 (12): (907-912). [PMID:22247788] [10.1021/op500134e] |
| 6. Weinberg LR, Albom MS, Angeles TS, Husten J, Lisko JG, McHugh RJ, Milkiewicz KL, Murthy S, Ott GR, Theroff JP et al.. (2011) Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors.. Bioorg Med Chem Lett, 21 (1): (164-7). [PMID:21123062] [10.1021/op500134e] |
| 7. Milkiewicz KL, Aimone LD, Albom MS, Angeles TS, Chang H, Grobelny JV, Husten J, Losardo C, Miknyoczki S, Murthy S et al.. (2011) Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.. Bioorg Med Chem, 19 (21): (6274-84). [PMID:21967808] [10.1021/op500134e] |
| 8. Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa JP et al.. (2014) The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.. Nature, 507 (7493): (508-12). [PMID:24553136] [10.1021/op500134e] |
| 9. Yan SB, Peek VL, Ajamie R, Buchanan SG, Graff JR, Heidler SA, Hui YH, Huss KL, Konicek BW, Manro JR et al.. (2013) LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.. Invest New Drugs, 31 (4): (833-44). [PMID:23275061] [10.1021/op500134e] |
| 10. Patwardhan PP, Ivy KS, Musi E, de Stanchina E, Schwartz GK. (2016) Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.. Oncotarget, 7 (4): (4093-109). [PMID:26675259] [10.1021/op500134e] |
| 11. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z, Lin G et al.. (2018) Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.. J Med Chem, 61 (24): (11398-11414). [PMID:30480444] [10.1021/op500134e] |
| 12. Qi B, Yang Y, Gong G, He H, Yue X, Xu X, Hu Y, Li J, Chen T, Wan X et al.. (2019) Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment.. Eur J Med Chem, 163 (13): (10-27). [PMID:30503936] [10.1021/op500134e] |
| 13. Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J, Ouyang L. (2016) Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.. Eur J Med Chem, 108 (13): (495-504). [PMID:26717201] [10.1021/op500134e] |
| 14. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ et al.. (2010) R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.. Cancer Res, 70 (4): (1544-54). [PMID:20145120] [10.1021/op500134e] |
| 15. Weihe Zhang,Dehui Zhang,Michael A Stashko,Deborah DeRyckere,Debra Hunter,Dmitri Kireev,Michael J Miley,Christopher Cummings,Minjung Lee,Jacqueline Norris-Drouin,Wendy M Stewart,Susan Sather,Yingqiu Zhou,Gregory Kirkpatrick,Mischa Machius,William P Janzen,H Shelton Earp,Douglas K Graham,Stephen V Frye,Xiaodong Wang. (2013-11-08) Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.. Journal of medicinal chemistry, 56 ((23)): (9683-9692). [PMID:24195762] |
| 16. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M.. (2007) Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice.. J Med Chem, 50 (23): (5579-5588). [PMID:17929792] [10.1021/jm061449r] |
| 17. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.. Proc Natl Acad Sci U S A, 104 (50): (19936-19941). [PMID:18077425] [10.1073/pnas.0707498104] |
| 18. Yu H, Jung Y, Kim H, Lee J, Oh CH, Yoo KH, Sim T, Hah JM.. (2010) 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.. Bioorg Med Chem Lett, 20 (12): (3805-3808). [PMID:20466542] [10.1016/j.bmcl.2010.04.039] |
| 19. Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, Gray NS, Sim T.. (2010) A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.. J Med Chem, 53 (15): (5439-5448). [PMID:20604564] [10.1021/jm901808w] |
| 20. Ebada SS, Schulz B, Wray V, Totzke F, Kubbutat MH, Müller WE, Hamacher A, Kassack MU, Lin W, Proksch P.. (2011) Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.. Bioorg Med Chem, 19 (15): (4644-4651). [PMID:21741249] [10.1016/j.bmc.2011.06.013] |
| 21. Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, Delaney A, Wang Y, Bourbonais F, Lee DY, Schwende F, Sun F, McConnell P, Catana C, Chen H, Ohren J, Perrin LA.. (2012) Novel and selective spiroindoline-based inhibitors of Sky kinase.. Bioorg Med Chem Lett, 22 (1): (190-193). [PMID:22119469] [10.1016/j.bmcl.2011.11.036] |
| 22. Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R, Xu J, Arnost M, Choquette D, Chen G, Zhou JH, Yao YM, Ball ED, Namchuk M, Davies RJ, Henkel G.. (2012) VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.. J Med Chem, 55 (2): (725-734). [PMID:22221201] [10.1021/jm201198w] |
| 23. Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, Earp HS, Graham DK, Frye SV, Wang X.. (2012) Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.. ACS Med Chem Lett, 3 (2): (129-134). [PMID:22662287] [10.1021/ml200239k] |
| 24. Li J, Hu H, Lang Q, Zhang H, Huang Q, Wu Y, Yu L.. (2013) A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.. Eur J Med Chem, 65 (151-157). [PMID:23707920] [10.1016/j.ejmech.2013.04.058] |
| 25. Li J, Wu N, Tian Y, Zhang J, Wu S.. (2013) Aminopyridyl/Pyrazinyl Spiro[indoline-3,4'-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors.. ACS Med Chem Lett, 4 (8): (806-810). [PMID:24900750] [10.1021/ml400203d] |
| 26. Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X.. (2013) Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.. J Med Chem, 56 (23): (9693-9700). [PMID:24219778] [10.1021/jm4013888] |
| 27. Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Orfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Orfi L, Vántus T, Kéri G.. (2014) Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.. ACS Med Chem Lett, 5 (4): (298-303). [PMID:24900830] [10.1021/ml4003309] |
| 28. Barcelos RC, Pelizzaro-Rocha KJ, Pastre JC, Dias MP, Ferreira-Halder CV, Pilli RA.. (2014) A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.. Eur J Med Chem, 87 (745-758). [PMID:25305718] [10.1016/j.ejmech.2014.09.085] |
| 29. Song Z, Yang Y, Liu Z, Peng X, Guo J, Yang X, Wu K, Ai J, Ding J, Geng M, Zhang A.. (2015) Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.. J Med Chem, 58 (1): (197-211). [PMID:24785465] [10.1021/jm5005144] |
| 30. Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, Cummings CT, Lee M, Glaros TG, Newton DL, Sather S, Zhang D, Kireev D, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X.. (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.. J Med Chem, 57 (16): (7031-7041). [PMID:25068800] [10.1021/jm500749d] |
| 31. Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ.. (2015) Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.. J Med Chem, 58 (6): (2746-2763). [PMID:25699576] [10.1021/jm501929n] |
| 32. Zhang CH, Zheng MW, Li YP, Lin XD, Huang M, Zhong L, Li GB, Zhang RJ, Lin WT, Jiao Y, Wu XA, Yang J, Xiang R, Chen LJ, Zhao YL, Cheng W, Wei YQ, Yang SY.. (2015) Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.. J Med Chem, 58 (9): (3957-3974). [PMID:25835317] [10.1021/acs.jmedchem.5b00270] |
| 33. Lin XD, Yang HW, Ma S, Li WW, Zhang CH, Wang WJ, Xiang R, Li LL, Yang SY.. (2015) Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.. Bioorg Med Chem Lett, 25 (20): (4534-4538). [PMID:26342867] [10.1016/j.bmcl.2015.08.068] |
| 34. Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G.. (2016) Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes.. Bioorg Med Chem Lett, 26 (2): (424-428). [PMID:26704265] [10.1016/j.bmcl.2015.11.099] |
| 35. Song D, Lee M, Park CH, Ahn S, Yun CS, Lee CO, Kim HR, Hwang JY.. (2016) Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.. Bioorg Med Chem Lett, 26 (7): (1720-1725). [PMID:26923695] [10.1016/j.bmcl.2016.02.052] |
| 36. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810] [10.1021/acs.jmedchem.6b00087] |
| 37. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800] [10.1016/j.bmcl.2016.04.079] |
| 38. Feneyrolles C, Guiet L, Singer M, Van Hijfte N, Daydé-Cazals B, Fauvel B, Chevé G, Yasri A.. (2017) Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors.. Bioorg Med Chem Lett, 27 (4): (862-866). [PMID:28094183] [10.1016/j.bmcl.2017.01.015] |
| 39. Ma F, Liu P, Lei M, Liu J, Wang H, Zhao S, Hu L.. (2017) Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).. Eur J Med Chem, 127 (72-86). [PMID:28038328] [10.1016/j.ejmech.2016.12.038] |
| 40. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H.. (2017) Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 60 (14): (6018-6035). [PMID:28714692] [10.1021/acs.jmedchem.7b00076] |
| 41. Zhao F, Zhang LD, Hao Y, Chen N, Bai R, Wang YJ, Zhang CC, Li GS, Hao LJ, Shi C, Zhang J, Mao Y, Fan Y, Xia GX, Yu JX, Liu YJ.. (2017) Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.. Eur J Med Chem, 134 (147-158). [PMID:28411455] [10.1016/j.ejmech.2017.03.085] |
| 42. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471] [10.1016/j.bmcl.2017.10.031] |
| 43. Liu H, Wu B, Ge Y, Huang J, Song S, Wang C, Yao J, Liu K, Li Y, Li Y, Ma X.. (2017) Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.. Bioorg Med Chem, 25 (24): (6313-6321). [PMID:29102081] [10.1016/j.bmc.2017.09.041] |
| 44. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448] [10.1016/j.bmc.2017.12.020] |
| 45. Myers SH, Temps C, Houston DR, Brunton VG, Unciti-Broceta A.. (2018) Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening.. J Med Chem, 61 (5): (2104-2110). [PMID:29466002] [10.1021/acs.jmedchem.7b01605] |
| 46. Baladi T, Aziz J, Dufour F, Abet V, Stoven V, Radvanyi F, Poyer F, Wu TD, Guerquin-Kern JL, Bernard-Pierrot I, Garrido SM, Piguel S.. (2018) Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.. Bioorg Med Chem, 26 (20): (5510-5530). [PMID:30309671] [10.1016/j.bmc.2018.09.031] |
| 47. Heng H, Wang Z, Li H, Huang Y, Lan Q, Guo X, Zhang L, Zhi Y, Cai J, Qin T, Xiang L, Wang S, Chen Y, Lu T, Lu S.. (2019) Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.. Eur J Med Chem, 176 (248-267). [PMID:31103903] [10.1016/j.ejmech.2019.05.021] |
| 48. Yuan T, Qi B, Jiang Z, Dong W, Zhong L, Bai L, Tong R, Yu J, Shi J.. (2019) Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.. Eur J Med Chem, 178 (468-483). [PMID:31207462] [10.1016/j.ejmech.2019.06.002] |
| 49. Bensinger D, Stubba D, Cremer A, Kohl V, Waßmer T, Stuckert J, Engemann V, Stegmaier K, Schmitz K, Schmidt B.. (2019) Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.. J Med Chem, 62 (5): (2428-2446). [PMID:30742435] [10.1021/acs.jmedchem.8b01714] |
| 50. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B.. (2019) Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.. Eur J Med Chem, 163 (671-689). [PMID:30572178] [10.1016/j.ejmech.2018.12.015] |
| 51. Baillache, Daniel J., Unciti-Broceta, Asier. (2020) Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. RSC Med Chem, 11 (10): (1112-1135). [PMID:33479617] [10.1039/d0md00227e] |
| 52. Zhou Y,Xu X,Wang F,He H,Gong G,Xiong L,Qi B. (2020) Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer.. Eur J Med Chem, 204 (112643-112643). [PMID:32731184] [10.1016/j.ejmech.2020.112643] |
| 53. Ebrahim HY,Mohyeldin MM,Hailat MM,El Sayed KA. (2016) (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.. Bioorg Med Chem, 24 (22.0): (5748-5761). [PMID:27681240] [10.1016/j.bmc.2016.09.032] |
| 54. O'Bryan, J P JP and 9 more authors.. (1991) axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.. Molecular and cellular biology, [PMID:1656220] |
| 55. Janssen, J W JW and 6 more authors.. (1991) A novel putative tyrosine kinase receptor with oncogenic potential.. Oncogene, [PMID:1834974] |
| 56. Partanen, J J, Mäkelä, T P TP, Alitalo, R R, Lehväslaiho, H H and Alitalo, K K.. (1990) Putative tyrosine kinases expressed in K-562 human leukemia cells.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2247464] |
| 57. Varnum, B C BC and 9 more authors.. (1995) Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6.. Nature, (16): [PMID:7854420] |
| 58. Craven, R J RJ and 8 more authors.. (1995) Receptor tyrosine kinases expressed in metastatic colon cancer.. International journal of cancer, (16): [PMID:7896447] |
| 59. Lee, S T ST, Strunk, K M KM and Spritz, R A RA.. (1993) A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes.. Oncogene, [PMID:8247543] |
| 60. Mark, M R MR, Chen, J J, Hammonds, R G RG, Sadick, M M and Godowsk, P J PJ.. (1996) Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl.. The Journal of biological chemistry, (19): [PMID:8621659] |
| 61. Braunger, J J and 7 more authors.. (1997) Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site.. Oncogene, (5): [PMID:9178760] |
| 62. Jacob, A N AN and 6 more authors.. (1999) A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a modified differential display PCR are overexpressed in metastatic prostatic carcinoma cell line DU145.. Cancer detection and prevention, [PMID:10403904] |
| 63. Berclaz, G G and 5 more authors.. (2001) Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast.. Annals of oncology : official journal of the European Society for Medical Oncology, [PMID:11484958] |
| 64. Hafizi, Sassan S, Alindri, Filiz F, Karlsson, Roger R and Dahlbäck, Björn B.. (2002) Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin.. Biochemical and biophysical research communications, (20): [PMID:12470648] |
| 65. Ito, Masahiro M and 8 more authors.. (2002) Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in pediatric thyroid carcinomas around chernobyl.. Thyroid : official journal of the American Thyroid Association, [PMID:12490074] |
| 66. Gallicchio, Margherita M and 6 more authors.. (2005) Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor.. Blood, (1): [PMID:15507525] |
| 67. Gould, W R WR and 6 more authors.. (2005) Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses.. Journal of thrombosis and haemostasis : JTH, [PMID:15733062] |
| 68. and Valverde, Paloma P.. (2005) Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation.. Biochemical and biophysical research communications, (22): [PMID:15958209] |
| 69. Shimojima, Masayuki M and 8 more authors.. (2006) Tyro3 family-mediated cell entry of Ebola and Marburg viruses.. Journal of virology, [PMID:17005688] |
| 70. Park, Il-Kyoo IK and 5 more authors.. (2009) The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development.. Blood, (12): [PMID:18840707] |
| 71. Pao-Chun, Lin L, Chan, Perry M PM, Chan, Wing W and Manser, Ed E.. (2009) Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling.. The Journal of biological chemistry, (11): [PMID:19815557] |
| 72. Morizono, Kouki K and 6 more authors.. (2011) The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry.. Cell host & microbe, (21): [PMID:21501828] |
| 73. Shimojima, Masayuki M, Ströher, Ute U, Ebihara, Hideki H, Feldmann, Heinz H and Kawaoka, Yoshihiro Y.. (2012) Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry.. Journal of virology, [PMID:22156524] |
| 74. Shimojima, Masayuki and Kawaoka, Yoshihiro.. (2012) Cell surface molecules involved in infection mediated by lymphocytic choriomeningitis virus glycoprotein.. The Journal of veterinary medical science, [PMID:22673088] |
| 75. and Thom, Claire C.. (2015) Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients.. Future oncology (London, England), [PMID:26279055] |
| 76. Antar, A A and 7 more authors.. (2017) Inhibition of FLT3 in AML: a focus on sorafenib.. Bone marrow transplantation, [PMID:27775694] |
| 77. Meertens, Laurent L and 16 more authors.. (2017) Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses.. Cell reports, (10): [PMID:28076778] |
| 78. Mori, Masamichi M and 8 more authors.. (2017) Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.. Investigational new drugs, [PMID:28516360] |
| 79. Chen, Jian J and 15 more authors.. (2018) AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling.. Nature microbiology, [PMID:29379210] |
| 80. Strange, Daniel P DP and 7 more authors.. (2019) Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human Sertoli Cells.. mBio, (16): [PMID:31311882] |
| 81. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H. (2018) A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.. Eur J Med Chem, 144 (13): (1-28). [PMID:29247857] [10.1021/op500134e] |
